Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 5—May 2006
Tuberculosis Special Section

Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis

Maria Elvira Balcells*1, Sara L. Thomas*, Peter Godfrey-Faussett*, and Alison D. Grant*Comments to Author 
Author affiliations: *London School of Hygiene and Tropical Medicine, London, United Kingdom

Main Article

Table 3

Studies comparing isoniazid treatment with no treatment in HIV-infected populations*

Author, country, dates Population Intervention/ comparison; blinding Enrolled (n) INH/control Follow up; loss to follow-up; overall or INH vs. control TB cases: culture positive/total (%)
Definition of INH resistance Resistant cases/total tested (% culture positive tested)
Risk for resistant TB/1,000
INH Controls INH Controls INH Controls RR (95% CI)
Randomized controlled trials
Gordin, USA, 1991–1996 (30) Clinic attendees; med. CD4 233/247 6 mo INH 300 mg daily vs. placebo; double blind 260/257 34 mo/33 mo; 6.2% vs. 7% NS/3 NS/6 NS 0/3 (NS) 0/5 (NS) 1.92† 1.94† 0.99 (0.06–6,298.19)
Hawken, Kenya, 1992–1997 (31) Clinic or VCT attendees; med. CD4 321.5/346 6 mo INH 300 mg daily/placebo; double blind 342/342 Med. 1.83 y (range 0–3.41); 32% vs. 27.3% not seen in final 6 m 19/25 (76) 22/23 (95.7) Growth on 0.2 μg/mL INH >1% growth on control medium 2/17 (90) 0/21 (96) 10.05† 1.46† 6.88 (0.01–3,882.85)
Mwinga, Zambia, 1992–1996 (33) VCT attendees 6 mo INH 900 mg twice weekly/placebo; double blind 350/352 Med. 1.8 y; 32.4% vs. 30.3% not seen in final 6 m NS/27 NS/44 NS 0/3 (NS) 1/5 (NS) 1.43† 26.38† 0.05 (0.00–30.47)
Johnson, Uganda, 1993–NS (34) Clinic or counseling attendees 6 mo INH 300 mg daily/placebo; partially double blind‡ 931/787 Mean 2 y/1.6 y (PPD+/anergic); 16.1% vs. 30.6% 36/51 (70.6) 46/64 (71.9) Growth on 0.1 μg/mL INH (BACTEC radiometric method) >1% growth on control medium 5/20 (56) 1/24 (52) 13.69 3.39 4.04 (0.50–32.80)
Rivero, Spain, 1994–2000 (35)
Clinic attendees; med. CD4 193/215
6 mo INH 300 mg daily/no treatment; not blind
24 mo; 26.8% vs. 7.8%
3/3 (100)
4/4 (100)
3/3 (100)
4/4 (100)
0.70 (0.16–3.05)
Cohort study
Moreno, Spain, 1985–1994 (32) Clinic attendees; med. CD4 689/648 9–12 mo INH (dose NS)/no treatment; not blind 29/92 89 mo vs. 60 mo; NS 3/3 (100) 39/43 (90.7) Growth on 0.2 μg/mL INH >1% growth on control medium 2/2 (67) 0/12 (31) 118.64† 5.41† 21.95 (0.04–11,582.31)

*INH, isoniazid; TB, tuberculosis; RR, relative risk; CI, confidence interval; med., median; NS, not stated; Rx, treatment; VCT, voluntary counseling and testing; PPD, purified protein derivative.
†Calculated by adding 0.5 to numerator and denominator of both groups.
‡Unclear whether isoniazid and placebo group received the same number of tablets.

Main Article

  1. Corbett  EL, Watt  CJ, Walker  N, Maher  D, Williams  BG, Raviglione  MC, The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:100921. DOIPubMedGoogle Scholar
  2. Selwyn  PA, Hartel  D, Lewis  VA, Schoenbaum  EE, Vermund  SH, Klein  RS, A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:54550. DOIPubMedGoogle Scholar
  3. Daley  CL, Small  PM, Schecter  GF, Schoolnik  GK, McAdam  RA, Jacobs  WR Jr, An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992;326:2315. DOIPubMedGoogle Scholar
  4. Di Perri  G, Cruciani  M, Danzi  MC, Luzzati  R, De  CG, Malena  M, Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet. 1989;2:15024.PubMedGoogle Scholar
  5. Mukadi  YD, Maher  D, Harries  A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS. 2001;15:14352. DOIPubMedGoogle Scholar
  6. De Cock  KM, Chaisson  RE. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis. 1999;3:45765.PubMedGoogle Scholar
  7. Woldehanna  S, Volmink  J. Treatment of latent tuberculosis infection in HIV infected persons (Cochrane Review). The Cochrane Library, Issue 3. Chichester (UK): John Wiley & Sons; 2004.
  8. World Health Organization Global Tuberculosis Programme, Joint United Nations Programme on HIV/AIDS. Policy statement on preventive therapy against tuberculosis in people living with HIV [cited 2006 Mar 20]. Geneva: The Organization; 1998. WHO/TB/98.255. Available from
  9. Ferebee  S. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res. 1970;17:28106.PubMedGoogle Scholar
  10. Smieja  MJ, Marchetti  CA, Cook  DJ, Smaill  FM. Isoniazid for preventing tuberculosis in non-HIV infected persons (Cochrane Review). The Cochrane Library, Issue 4. Chichester (UK): John Wiley & Sons; 2003.
  11. Wilkinson  D, Squire  SB, Garner  P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. BMJ. 1998;317:6259. DOIPubMedGoogle Scholar
  12. Bucher  HC, Griffith  LE, Guyatt  GH, Sudre  P, Naef  M, Sendi  P, Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS. 1999;13:5017. DOIPubMedGoogle Scholar
  13. Sankey  SS, Weissfeld  LA, Fine  MJ, Kapoor  WN. An assessment of the use of the continuity correction for sparse data in meta-analysis. Comm Statist Simulation Comput. 1996;25:103156. DOIGoogle Scholar
  14. DerSimonian  R, Laird  N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:17788. DOIPubMedGoogle Scholar
  15. Gomez  JE, McKinney  JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb). 2004;84:2944. DOIPubMedGoogle Scholar
  16. David  HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol. 1970;20:8104.PubMedGoogle Scholar
  17. Begg  CB, Mazumdar  M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088101. DOIPubMedGoogle Scholar
  18. Ferebee  SH, Mount  FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis. 1962;85:490510.PubMedGoogle Scholar
  19. Katz  J, Kunofsky  S, Damijonaitis  V, Lafleur  A, Caron  T. Effect of isoniazid upon the reactivation of inactive tuberculosis; final report. Am Rev Respir Dis. 1965;91:34550.PubMedGoogle Scholar
  20. Horwitz  O, Payne  PG, Wilbek  E. Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland. Bull World Health Organ. 1966;35:50926.PubMedGoogle Scholar
  21. Comstock  GW, Ferebee  SH, Hammes  LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis. 1967;95:93543.PubMedGoogle Scholar
  22. Pamra  SP, Mathur  GP. Effects of chemoprophylaxis on minimal pulmonary tuberculosis lesions of doubtful activity. Bull World Health Organ. 1971;45:593602.PubMedGoogle Scholar
  23. Debre  R, Perdrizet  S, Lotte  A, Naveau  M, Lert  F. Isoniazid chemoprophylaxis of latent primary tuberculosis: in five trial centres in France from 1959 to 1969. Int J Epidemiol. 1973;2:15360. DOIPubMedGoogle Scholar
  24. Grzybowski  S, Ashley  MJ, Pinkus  G. Chemoprophylaxis in inactive tuberculosis: long-term evaluation of a Canadian trial. Can Med Assoc J. 1976;114:60711.PubMedGoogle Scholar
  25. Krebs  A. The IUAT trial on isoniazid preventive treatment in persons with fibrotic lung lesions. Bull Int Union Tuberc. 1976;51:193201.PubMedGoogle Scholar
  26. Nolan  CM, Aitken  ML, Elarth  AM, Anderson  KM, Miller  WT. Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. Am Rev Respir Dis. 1986;133:4316.PubMedGoogle Scholar
  27. British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis. 1992;145:3641. DOIPubMedGoogle Scholar
  28. Pape  JW, Jean  SS, Ho  JL, Hafner  A, Johnson  WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993;342:26872. DOIPubMedGoogle Scholar
  29. Guelar  A, Gatell  JM, Verdejo  J, Podzamczer  D, Lozano  L, Aznar  E, A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS. 1993;7:13459. DOIPubMedGoogle Scholar
  30. Gordin  FM, Matts  JP, Miller  C, Brown  LS, Hafner  R, John  SL, A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med. 1997;337:31520. DOIPubMedGoogle Scholar
  31. Hawken  MP, Meme  HK, Elliott  LC, Chakaya  JM, Morris  JS, Githui  WA, Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS. 1997;11:87582. DOIPubMedGoogle Scholar
  32. Moreno  S, Miralles  P, Diaz  MD, Baraia  J, Padilla  B, Berenguer  J, Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival. Arch Intern Med. 1997;157:172934. DOIPubMedGoogle Scholar
  33. Mwinga  A, Hosp  M, Godfrey-Faussett  P, Quigley  M, Mwaba  P, Mugala  BN, Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS. 1998;12:244757. DOIPubMedGoogle Scholar
  34. Johnson  JL, Okwera  A, Hom  DL, Mayanja  H, Kityo  CM, Nsubuga  P, Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS. 2001;15:213747. DOIPubMedGoogle Scholar
  35. Rivero  A, Lopez-Cortes  L, Castillo  R, Lozano  F, Garcia  MA, Diez  F, Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy [in Spanish]. Enferm Infecc Microbiol Clin. 2003;21:28792. DOIPubMedGoogle Scholar
  36. Rieder  HL, Chonde  MT, Myking  H, Urbaniczik  R, Laszlo  A, Kim  SJ, The public health service national tuberculosis reference laboratory and the national laboratory network: minimum requirements, role and operation in a low-income country. Paris: International Union against Tuberculosis and Lung Disease; 1998.
  37. Sonnenberg  P, Murray  J, Glynn  JR, Shearer  S, Kambashi  B, Godfrey-Faussett  P. HIV-1 and recurrence, relapse and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001;358:168793. DOIPubMedGoogle Scholar
  38. van Rie  A, Warren  R, Richardson  M, Victor  TC, Gie  RP, Enarson  DA, Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med. 1999;341:11749. DOIPubMedGoogle Scholar
  39. Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:7359.PubMedGoogle Scholar
  40. World Health Organization. Interim policy on collaborative TB/HIV activities. Geneva: The Organization; 2004. WHO/HTM/TB/2004.330. Available from

Main Article

1Current affiliation: Department of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Page created: January 12, 2012
Page updated: January 12, 2012
Page reviewed: January 12, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.